Compare HUBG & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HUBG | STOK |
|---|---|---|
| Founded | 1971 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 1996 | 2019 |
| Metric | HUBG | STOK |
|---|---|---|
| Price | $24.47 | $26.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 14 |
| Target Price | $37.17 | ★ $46.38 |
| AVG Volume (30 Days) | 756.9K | ★ 1.2M |
| Earning Date | 11-24-2026 | 10-29-2026 |
| Dividend Yield | ★ 2.05% | N/A |
| EPS Growth | N/A | ★ 92.73 |
| EPS | ★ 1.34 | N/A |
| Revenue | ★ $3,946,390,000.00 | $184,420,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.45 | $45.99 |
| P/E Ratio | $18.18 | ★ N/A |
| Revenue Growth | N/A | ★ 404.50 |
| 52 Week Low | $23.90 | $22.05 |
| 52 Week High | $53.26 | $40.22 |
| Indicator | HUBG | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 35.81 | 50.48 |
| Support Level | N/A | $24.21 |
| Resistance Level | $28.05 | $33.39 |
| Average True Range (ATR) | 1.05 | 1.21 |
| MACD | 0.05 | 0.10 |
| Stochastic Oscillator | 14.60 | 40.53 |
Hub Group ranks among the largest providers of rail intermodal service. Approximately 60% of consolidated revenue comes from Hub's intermodal and transportation solutions division. ITS includes its flagship intermodal operations, which use the Class I rail carriers for the underlying line-haul movement of containers, as well as its dedicated truckload shipping unit. Hub's logistics segment includes its asset-light truck brokerage operations along with its outsourced transportation management, warehousing and fulfillment, and heavy-goods final mile delivery offerings. Hub often makes tuck-in acquisitions that expand its brokerage, last-mile, and dedicated offerings.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.